Dr. Michael Murphy leads an invigorating panel discussion with a rare disease patient and other industry experts. Each share their experience with rare disease trials along with their thoughts on the road ahead in a post-COVID environment.

Discussion points include:

• Balancing and improving the interest of the patients, site and sponsor
• Connecting rare disease patients with medical experts for studies
• Feasibility and the differences seen in rare disease trials
• The importance of patient advocacy groups as an ancillary partner
• Benefits and challenges of study visits for rare disease trial patients